体外肺灌注系统（EVLP）因能持续温血灌注供肺并可评估修复供肺功能而备受青睐，但因灌注时间延长导致的系统血栓形成及供肺血管内皮栓塞限制了EVLP的推广应用。乳脂球表皮生长因子8（MFG-E8）是一种位于细胞膜上的亲脂性糖蛋白，具有靶向清除活化的血小板及促凝微粒，预防血栓形成而不引起出血等有别于常规抗凝药物的独特优点。我们前期研究还发现MFG-E8可强力抑制炎性反应，有效保护急性肺损伤。鉴于MFG-E8这些独特的生物学作用，本课题拟通过建立EVLP动物模型，将MFG-E8加入EVLP灌注液中，探讨MFG-E8预防EVLP系统血栓形成和供肺血管内皮栓塞的作用，并通过体外实验探讨MFG-E8对血管内皮微颗粒功能的影响及肺微血管内皮细胞的保护作用及机制，以期为预防EVLP系统血栓形成和供肺血管内皮栓塞，改善肺移植离体肺保护效果方面的研究提供一条新的策略和思路。

Ex vivo lung perfusion (EVLP) is nowadays a favored technique for its ability to evaluate, assess and recondition lung grafts via maintaining continuous warm blood perfusion. However, the application of EVLP is limited by thrombosis and pulmonary endothelial embolism due to prolonged perfusion time . Milk fat globule epidermal growth factor 8(MFG-E8), a glycoprotein secreted by macrophages, promotes phagocytosis of activated platelets and phosphatidyl serine-rich platelet derived micro-vesicles,but does not affect resting platelets, which could prevent thrombosis but without increasing bleeding risk. We have previously shown that MFG-E8 plays an important role in the protection of acute ischemia reperfusion injury of lung. All of these properties suggest that MFG-E8 may be superior to unfractionated heparin or bivalirudin for the strategy for prevention of thrombosis within the EVLP while at the same time minimizing the bleeding risk. In view of these unique biological effects of MFG-E8, this study is to investigate the possible protective effects and mechanisms of MFG-E8 on the prevention of thrombosis and pulmonary endothelial embolism in ex vivo lung perfusion by swine EVLP and lung transplantation model in vivo and the cell culture of human vein endothelial cell and pulmonary microvascular endothelial cell in vitro . The findings of this study might provide a new strategy and a beneficial approach to the prevention of thrombosis and pulmonary endothelial embolism in ex vivo lung perfusion as well as to improve the function of lung grafts and outcome of EVLP .